Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
17.24
+0.42 (2.50%)
At close: Jul 24, 2026, 4:00 PM EDT
17.02
-0.22 (-1.25%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Takeda Pharmaceutical Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 4,505,700 | 4,505,700 | 4,581,551 | 4,263,762 | 4,027,478 | 3,569,006 |
Revenue Growth | -1.66% | -1.66% | 7.45% | 5.87% | 12.85% | 11.61% |
Gross Profit Gross Profit Growth | 2,934,145 | 2,934,100 | 3,001,334 | 2,837,084 | 2,783,406 | 2,462,160 |
Operating Income Operating Income Growth | 6,200 | 6,200 | 342,586 | 214,075 | 490,505 | 460,844 |
Net Income Net Income Growth | 191,741 | -142,400 | 108,143 | 144,197 | 317,017 | 230,059 |
Earnings Per Share EPS Growth | -48.38 | -48.38 | 33.62 | 45.58 | 100.97 | 72.94 |
EPS Growth | - | - | -26.25% | -54.86% | 38.44% | -38.96% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
GI GI Growth | 1,407,460 | 1,407,460 | 1,357,022 | 1,216,207 | 1,094,541 |
Rare Diseases Rare Diseases Growth | 762,698 | 762,698 | 752,816 | 688,423 | 639,774 |
PDT PDT Growth | 1,057,524 | 1,057,524 | 1,032,662 | 903,699 | 763,359 |
Oncology Oncology Growth | 580,126 | 580,126 | 560,430 | 462,362 | 438,742 |
Vaccines Vaccines Growth | 59,607 | 59,607 | 55,412 | 50,355 | 78,664 |
Neuroscience Neuroscience Growth | 414,343 | 414,343 | 565,816 | 627,014 | 637,711 |
Other Product Other Product Growth | 223,961 | 223,961 | 257,392 | 315,701 | 372,685 |
Revenue (Total) Revenue (Total) Growth | 4,505,700 | 4,505,700 | 4,581,551 | 4,263,762 | 4,027,478 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 636,942 | 636,942 | 405,589 | 472,889 | 553,704 | 875,000 |
Total Debt Total Debt Growth | 4,881,838 | 4,881,838 | 4,515,265 | 4,843,752 | 4,382,341 | 4,345,411 |
Net Cash (Debt) Net Cash Growth | -4,244,896 | -4,244,896 | -4,109,676 | -4,370,863 | -3,828,637 | -3,470,411 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1347.53 | -1347.53 | -1280.02 | -1382.88 | -1219.41 | -1100.20 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 1,041,431 | 1,041,431 | 1,057,182 | 716,344 | 977,156 | 1,123,105 |
Capital Expenditures CapEx Growth | -176,003 | -176,003 | -200,795 | -175,420 | -140,657 | -123,252 |
Free Cash Flow Free Cash Flow Growth | 865,428 | 865,428 | 856,387 | 540,924 | 836,499 | 999,853 |
Free Cash Flow Growth | 1.06% | 1.06% | 58.32% | -35.34% | -16.34% | 11.13% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 65.12% | 65.12% | 65.51% | 66.54% | 69.11% | 68.99% |
Operating Margin | 0.14% | 0.14% | 7.48% | 5.02% | 12.18% | 12.91% |
Pretax Margin | -3.16% | -3.16% | 3.82% | 1.24% | 9.31% | 8.48% |
Profit Margin | 4.26% | -3.16% | 2.36% | 3.38% | 7.87% | 6.45% |
FCF Margin | 19.21% | 19.21% | 18.69% | 12.69% | 20.77% | 28.01% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 25, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.492 | 200.000 | 196.000 | 188.000 | 180.000 | 180.000 |
Dividend Per Share Growth | -9.35% | 2.04% | 4.25% | 4.44% | 0% | 0% |
Dividend Yield | 2.86% | 3.37% | 4.30% | 4.36% | 4.11% | 5.20% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 25, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | 66.32 | 46.15 | 21.67 | 23.91 |
P/FCF Ratio | 10.43 | 10.72 | 8.19 | 12.20 | 8.13 | 5.52 |
PS Ratio | 1.94 | 2.06 | 1.53 | 1.55 | 1.69 | 1.55 |